Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Gains from Sales and Divestitures (2021 - 2026)

Journey Medical filings provide 5 years of Gains from Sales and Divestitures readings, the most recent being $944946.0 for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 10.72% to $944946.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $944946.0, a 10.72% decrease, with the full-year FY2025 number at $944946.0, down 10.72% from a year prior.
  • Gains from Sales and Divestitures hit $944946.0 in Q4 2025 for Journey Medical, up from $927446.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.1 million in Q4 2024 to a low of $2000.0 in Q1 2022.
  • Median Gains from Sales and Divestitures over the past 5 years was $293707.0 (2022), compared with a mean of $427501.5.
  • Biggest five-year swings in Gains from Sales and Divestitures: skyrocketed 3333.1% in 2023 and later crashed 76.11% in 2025.
  • Journey Medical's Gains from Sales and Divestitures stood at $136500.0 in 2021, then soared by 115.17% to $293707.0 in 2022, then surged by 147.61% to $727249.0 in 2023, then soared by 45.53% to $1.1 million in 2024, then dropped by 10.72% to $944946.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $944946.0 (Q4 2025), $927446.0 (Q3 2025), and $324159.0 (Q2 2025) per Business Quant data.